Key Points for Decision Makers {#FPar1}
==============================

This study suggests that at a group level people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are more disabled than people affected by multiple sclerosis (MS), as measured by the SF-36v2™.ME/CFS is associated with a reduction in time spent at work and lower income, compared with people affected by MS.Further efforts should be made to identify and address the impact of ME/CFS to individuals and society.

Introduction {#Sec1}
============

While the majority of people with disabilities seek to be recognised first as individuals, independent of their disability \[[@CR1]\], people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) continue to campaign to have their disease recognised as disabling \[[@CR2]\]. However, research into disability in ME/CFS has been hampered by a lack of consensus, both around the definition of the disease and appropriate measurement tools \[[@CR3], [@CR4]\].

ME/CFS is a poorly understood disease. Its measured population prevalence varies between 0.1 and 2.5% \[[@CR5]--[@CR8]\] according to the definition used, the place and context in which the definition is used, and user perceptions. There is currently no validated test available that can distinguish people with the disease from those without, and, in the absence of a diagnostic marker \[[@CR9]\], definitions continue to challenge the medical and research communities \[[@CR10]\]. The definitions most widely used by researchers are the US Centers for Disease Control and Prevention (CDC) 1994 case definition \[[@CR11]\], the Canadian Consensus Criteria (CCC) \[[@CR12]\] and the International Consensus Criteria (ICC) for ME \[[@CR13]\], all of which require the exclusion of other illnesses, except for certain comorbidities.

In adults, ME/CFS is characterised by unexplained persistent or recurrent incapacitating fatigue of more than 6 months' duration accompanied by a range of symptoms that vary within and between individuals. All definitions include a restricted ability to maintain the level of occupational, educational, social and personal activities previously enjoyed \[[@CR14]--[@CR16]\].

The diversity and fluctuating nature of symptoms, the absence of a diagnostic test and the lack of a universally accepted definition have combined to make ME/CFS a disease stigmatised by both the medical community and the public \[[@CR17]--[@CR21]\]. This has likely contributed to limited united efforts by the research community and very restricted funding from government and other mainstream research funders compared with other similarly debilitating illnesses, despite its prevalence and impact \[[@CR22], [@CR23]\].

There is little research to quantify health-related quality of life (HRQoL) in people with ME/CFS. Previous research using the Medical Outcomes Survey Short Form-36 v2™ (SF-36v2™) published in 2011 \[[@CR24]\] indicated that ME/CFS impacted the status and well-being of people with well-characterised ME/CFS to a greater extent than 10 other chronic diseases, including cancer. A Danish study published soon thereafter showed that the HRQoL of people in the study with ME/CFS was the lowest of all conditions compared \[[@CR25]\], including cancer, diabetes, long- and short-term mental illness, stroke, osteoarthritis and rheumatoid arthritis. Both studies relied on general population and disease-specific norms for the comparison groups to show the disabling effects of ME/CFS; a comparison with healthy and diseased groups from the same geographical area from where the cases were provided would likely be more accurate. Furthermore, participants in the Danish study self-reported their diagnosis of ME/CFS, which may have led to selection bias.

In this study, the SF-36v2^TM^ questionnaire was used to compare functional status and well-being in people with ME/CFS and two matched comparison groups---people with MS (PWMS) and healthy controls (HCs).

Methods {#Sec2}
=======

This cross-sectional study compared SF-36v2^TM^ scores \[[@CR26]\] collected from participants in the recently established UK ME/CFS Biobank \[[@CR27]\]. The Biobank cohort included people with ME/CFS, PWMS and HCs who had provided data and samples for future research. The data were collected between December 2013 and February 2015 from a population resident in the same geographic area. Participants in the UK ME/CFS Biobank with ME/CFS and MS needed a medically confirmed diagnosis, and people with ME/CFS were required to meet the CDC 1994 \[[@CR11]\] or Canadian criteria \[[@CR12]\].

PWMS were chosen as a suitable comparison group because (1) both ME and MS are classified as a neurological disease in the World Health Organization's International Classification of Diseases, Tenth Revision (ICD-10; G93.3) \[[@CR28]\]; and (2) MS (ICD-10; G35) also presents with fluctuating chronic fatigue and a number of other similar symptoms, including orthostatic intolerance and cognitive impairment \[[@CR29]\].

Recruitment for the UK Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Biobank {#Sec3}
------------------------------------------------------------------------------------------

Between 2012 and 2015, the UK ME/CFS Biobank collected data and samples from participants in London and East Anglia; details of the UK ME/CFS Biobank protocol have been previously published \[[@CR27]\]. Participants were recruited through National Health Service general practices and specialist services with support from the National Institute for Health Research (NIHR) clinical and research networks. Staff from the local NIHR Clinical Research Network (formerly the Primary Care Research Network) approached general practices in Norfolk and Suffolk to seek willingness to recruit participants. Once local ethical approval was in place, participating practices sent letters to registered patients with a diagnosis of ME/CFS, people with a diagnosis of MS, and potential HCs, inviting them to participate in the study. Three HCs were invited for each person with ME/CFS to be recruited. A higher response and recruitment rate was anticipated from people with the disease because people with ME/CFS are underrepresented in research studies and are therefore motivated to participate \[[@CR34]\]. At the same time, specialty clinics in London, Norfolk and Suffolk approached their patients with ME/CFS and MS. Posters seeking HC volunteers were placed in general practice surgeries and institutes of higher education in the same regions. A full description of recruitment procedures can be found in the paper describing the establishment of the UK ME/CFS Biobank \[[@CR27]\].

All participants conformed to the inclusion/exclusion criteria described in Table [1](#Tab1){ref-type="table"}. The study protocol was identical for all participants, regardless of category of recruitment, although questions related to MS and ME/CFS were omitted for HCs.Table 1UK Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Biobank: inclusion and exclusion criteriaInclusion criteria\
 Age 18--60 years\
 ME/CFS cases must have a clinical diagnosis using CCC \[[@CR10]\] and/or CDC 1994 \[[@CR23]\] criteria\
 MS cases must have a confirmed diagnosis made by an NHS consultant neurologist according to NICE guidelines\
 Informed consent givenExclusion criteria\
 Recent (in the preceding 3 months) use of drugs known to alter immune function (e.g. azathioprine, cyclosporine, methotrexate, corticosteroids), use of antiviral medications, or vaccination\
 History of acute or chronic infectious diseases such as hepatitis B and C, tuberculosis,  HIV (but not herpes virus or other retrovirus infection)\
 Other severe illnesses\
 Psychiatric diagnosis (e.g. schizophrenia or severe mood disorder, such as current severe depression)\
 Pregnant women and those within 12 months' post-partum and/or currently lactating\
 For ME/CFS and MS cases, other conditions that could explain their chronic fatigue\
 For healthy controls, current or past fatiguing illness and/or other major morbidity*ME* myalgic encephalomyelitis, *CFS* chronic fatigue syndrome, *CCC* Canadian Consensus Criteria, *CDC* Centers for Disease Control and Prevention, *MS* multiple sclerosis, *NHS* National Health Service, *NICE* National Institute for Health and Care Excellence, *HIV* human immunodeficiency virus

A clinical researcher assessed all potential Biobank participants at the recruitment stage using a bespoke 'Symptoms Assessment' form to confirm eligibility to participate in the study. All participants donated blood (some of which was used for clinical tests to exclude alternative diagnoses), completed a clinical assessment, and filled out study questionnaires, including the SF-36v2^TM^ and the 'Participant Questionnaire'. Together, these tools enabled the characterisation of participants with ME/CFS and MS according to clinical phenotype and disease severity.

Sample Size for the Proposed Analysis {#Sec4}
-------------------------------------

A subsample of 156 individuals (52 with ME/CFS, 52 with MS, and 52 HCs) was drawn from the Biobank cohort. The participants with ME/CFS were randomly drawn from the list of recruited participants and matched by sex and age group with individuals from the control groups. This sample size was considered sufficient to detect differences in SF-36v2^TM^ mean/median scores ≥ 5 between people with ME/CFS and each of the two comparison subgroups, with a power of 90% and at a significance level of 0.05 using norm-based scores. We used a conservative 5-point difference in norm-based scores as the minimally important difference (MID), even though the recommended MID varies among the summary measures and each specific domain. For example, an MID of 2--3 points is considered reasonable for the Physical Component Summary (PCS) domain \[[@CR26]\], based on clinical trials with patients with peripheral arterial disease. Using a similar approach in different trials, Ware et al. suggested different MIDs for the SF-36v2^TM^ scales, ranging from 3.1 to 5.7, the higher MID being recommended for the General Health (GH) domain (5.7), Vitality (VT) domain (5.5) and the Mental Health (MH) domain (5.5). The MIDs recommended for the summary measures were 3.1 (PCS) and 3.8 (Mental Component Summary; MCS) \[[@CR26]\].

Data Collection {#Sec5}
---------------

The SF-36v2^TM^ is a health survey that uses 36 questions to collect information about functional status and well-being from respondents. These questions evolved from medical outcome studies carried out in the 1980s and 1990s, and were developed with psychometric rigour to ensure that the information captured was reliable \[[@CR26]\]. The answers to these unambiguous questions form eight different scales, known as domains. Reports from studies using this instrument evidenced an increase in reliability and validity of scores in a diverse range of populations and settings when compared with other outcome measure instruments \[[@CR30]\]. The SF-36v2^TM^ is recognised as a reliable tool that uses generic health measures that are not age-, disease- or treatment-specific; it has been used and validated across different populations \[[@CR31]\]. The version used employs language familiar to people living in the UK \[[@CR32]\]. A full report on the development of this research instrument, and a detailed description of its ability to access functional status and well-being, has been published elsewhere \[[@CR26]\].

The SF-36v2^TM^ considers physical and mental functions resulting in eight distinct domains, which are summarised into the PCS and the MCS \[[@CR26]\]. The PCS comprises four domains and is used to profile functional health: Physical Function (PF) measures the ability to undertake everyday activities; Role Physical (RP) measures limitations in the ability to work; Bodily Pain (BP) measures the impact of pain on activity; and GH looks at the general health perceptions of the respondent. Low scores in the PCS indicate reduced functional status.

The four domains making up the MCS are measures of VT, with questions about energy and tiredness; Social Function (SF); MH, which asks about psychological well-being, anxiety and depression; and Role Emotional (RE), which considers role limitations due to emotional problems. Since the VT domain is included in the MCS, the physical symptoms of ME/CFS and MS, especially fatigue, are likely to reduce that score, which should be borne in mind when interpreting results.

In this study, the SF-36v2^TM^ instrument was used to compare disability (measuring functional status and well-being) and served to assess HRQoL. In addition to the SF-36v2^TM^ questionnaire, all Biobank participants also completed the Participant Questionnaire, which was developed by the UK ME/CFS Biobank team to capture information on socioeconomic, demographic, clinical and family history, and which was piloted prior to its use. Most of its questions about symptoms were taken from validated questionnaires \[[@CR27], [@CR33]--[@CR35]\]. Examples of the questions on employment and income used in the Participant Questionnaire can be seen in Online Appendix 1.

The time lag between disease onset and the response to the questionnaires varied between participants. For the analyses carried out for this study, we used the resultant demographic (sex and age), clinical (functional status and well-being), and socioeconomic (education, accommodation, employment, and income) data. Income data refers to income at the time of recruitment and, when relevant, to 6 months before the disease showed symptoms.

Data Analysis {#Sec6}
-------------

Answers to the SF-36v2^TM^ questions were scored in health domains grouped into the PCS and the MCS using the SF Health Outcomes™ Scoring Software 4.5 \[[@CR36]\]. Although actual scores for individual questions may vary within the general population, these average scores become 50 out of a possible 100 across all questions when they are norm-based with an SD (*σ*) of 10 \[[@CR26]\]. Therefore, norm-based scores compare results with others who have completed the SF-36v2^TM^ rather than against fixed criteria.

Data were analysed using Stata 14.0 software \[[@CR37]\]. Bivariate analyses were used to compare people with ME against PWMS or HCs using the Chi-square test and Chi-square for trend to assess the association between categorical variables; the *t* test or Wilcoxon rank-sum test were used for continuous variables.

In addition to using the SF-36v2^TM^ scores, we also looked at the effect of ME/CFS on some socioeconomic variables, which could also impact HRQoL. For these analyses, we used the variables 'current income', 'employment', 'hours of work' and 'benefits', using conditional logistic regression as recommended for paired design \[[@CR38]\].

Results {#Sec7}
=======

Description of the Study Population {#Sec8}
-----------------------------------

The study population came from South East England, was predominantly female (73%), of working age (mean age was 49.4 years), and most had completed higher education. Social demographic characteristics are shown in Table [2](#Tab2){ref-type="table"}.Table 2Social demographics of the study sampleCharacteristicsPeople with ME/CFS \[*n* = 52\]Healthy controls \[*n* = 52\]*P* value^a^ \[ME/HCs\]People with MS \[*n* = 52\]*P* value^a^ \[ME/MS\]Mean age, years49.349.40.7649.40.85Female38 (73)38 (73)--38 (73)--Education\[*n* = 52\]\[*n* = 52\]0.88\[*n* = 51\]0.33 Up to GCSE^b^17 (32.7)14 (26.9)--18 (35.3)-- Completed school and began higher education8 (15.4)10 (19.2)--9 (17.7)-- Completed higher education15 (28.9)17 (32.7)--19 (37.3)-- Postgraduate education12 (23.1)11 (21.1)--5 (9.8)--Accommodation0.20.6 Owned or mortgaged38 (73.1)44 (84.7)--38 (73.1)-- Rented9 (17.3)8 (15.4)--13 (25)-- Other arrangements5 (9.6)----1 (1.9)--Data are expressed as *n* (%)*ME* myalgic encephalomyelitis, *CFS* chronic fatigue syndrome, *HCs* healthy controls, *MS* multiple sclerosis, *GCSE* General Certificate of Secondary Education^a^Chi-square test or Chi-square for trend, or the Wilcoxon rank-sum test^b^Secondary school examinations typically taken at the age of 16 years in the UK

The SF-36v2^TM^ responses were analysed from the subsample of participants matched by age and sex, i.e. 52 people with ME/CFS (as per study), 52 PWMS, and 52 HCs, and most participants came from greater London or East Anglia. Of the 52 participants with ME/CFS, 75% had mild--moderate symptoms and 25% had severe symptoms, reflecting an intentional recruitment ratio. Of those with MS who responded to the question (*n* = 42), 71% had remitting-relapsing MS and 29% had primary- or secondary-progressive MS.

SF-36v2^TM^ Comparison Scores {#Sec9}
-----------------------------

The SF-36v2^TM^ median scores, compared by groups, are shown in Fig. [1](#Fig1){ref-type="fig"}, which presents median scores for individual scales as well as the PCS and MCS. This figure is a spider chart, where axes radiate outwards from a central point (0), with each axis representing an SF-36v2^TM^ scale or component summary. The median scores found for the scales and component summaries in each group were plotted on the axes in the spider chart. By joining the points on the axes by group, the resulting polygons clearly displayed the differences in scores from people with ME/CFS (smaller polygon reflects lower scores), PWMS and HCs (higher scores); apart from RE, these differences were all statistically significant. Median SF-36v2^TM^ scores from people with ME/CFS were consistently below those for both HCs (*p* \< 0.001 for all domains and summary measures) and PWMS (*p* \< 0.03 for MH scores, and *p* \< 0.001 for the remaining domains, except for RE, which was 0.12). SF scores, at 27 and 57 for people with ME/CFS and HCs, respectively, showed the largest difference (*p* \< 0.001).Fig. 1Median SF-36v2^TM^ scores for people with ME/CFS, people with MS, and healthy controls. *ME* myalgic encephalomyelitis, *CFS* chronic fatigue syndrome, *MS* multiple sclerosis

Socioeconomic Impact {#Sec10}
--------------------

### Work and Study Hours {#Sec11}

Six months before illness onset, the profiles of hours of study and work (including unpaid and voluntary work, and looking after the home) for people with ME/CFS and PWMS were similar, suggesting that prior to disease onset people in both disease groups were equally active in work and study. Moreover, the pre-illness profiles were similar to those of the HCs.

At recruitment (Fig. [2](#Fig2){ref-type="fig"}), 74% of people with ME/CFS were working and/or studying for 16 or fewer hours/week compared with 26% of PWMS and 12% of HCs. Comparing people with ME/CFS pre- and post disease onset, we found that the number of those spending fewer than 17 h per week at work or study increased more than fourfold (from 17.6% to 76.4%). In this study population, almost 60% of HCs reported working and/or studying more than 40 h/week, compared with 10% of people with ME/CFS (*p* \< 0.05).Fig. 2Weekly hours of work and study for healthy controls, people with ME/CFS, and people with MS, at recruitment (post-disease onset). *ME* myalgic encephalomyelitis, *CFS* chronic fatigue syndrome, *MS* multiple sclerosis

### Employment {#Sec12}

Disease onset had a greater impact on employment among people with ME/CFS than among PWMS (Fig. [3](#Fig3){ref-type="fig"}), in both working status and number of hours worked. While over 89% (*n* = 45) of people with ME/CFS had been employed before disease onset, this reduced to 35% (*n* = 18) after illness onset, which compares with 93% of PWMS before (*n* = 48) and 60% of PWMS (*n* = 52) after disease onset.Fig. 3Employment status of people with ME/CFS and people with MS, at two time points: 6 months before disease onset, and at recruitment. *ME* myalgic encephalomyelitis, *CFS* chronic fatigue syndrome, *MS* multiple sclerosis

Only 13% of people with ME/CFS and 37% of PWMS worked full time at the time of recruitment, with 52% of people with ME/CFS and 27% of PWMS self-identifying as 'sick or disabled', although the differences between the groups did not reach statistical significance (*p* = 0.07).

### Income {#Sec13}

The income of people with ME/CFS and PWMS prior to disease onset followed a normal distribution and there was no statistical difference between the two categories (*p* = 0.63). Free-text data showed that all people with ME/CFS and PWMS who had not been receiving any income were in full-time education.

The annual income of people with ME/CFS after disease onset was lower than it had been 6 months before disease onset (Fig. [4](#Fig4){ref-type="fig"}). The percentage of people with ME/CFS earning more than £30,000 more than halved following disease onset.Fig. 4Annual income of people with ME/CFS 6 months prior to disease onset and at recruitment. *ME* myalgic encephalomyelitis, *CFS* chronic fatigue syndrome, *PWME* people with ME/CFS

Post disease onset, 83% of people with ME/CFS earned below £20,000, compared with 59% of PWMS and 54% of HCs (Fig. [5](#Fig5){ref-type="fig"}), although these differences were not statistically significant (*p* = 0.24). Some participants did not provide information on income (8% of people with ME/CFS and 12% of PWMS).Fig. 5Annual income of people with ME/CFS, people with MS, and HCs at recruitment. *ME* myalgic encephalomyelitis, *CFS* chronic fatigue syndrome, *MS* multiple sclerosis, *HCs* healthy controls

Despite the degenerative component that is often part of the natural history of MS, changes in income for PWMS were smaller, at 7.6%, following illness onset. In contrast, the number of people with ME/CFS who earned below £10,000 increased by 82%.

Conditional Logistic Regression Bivariate Analysis {#Sec14}
--------------------------------------------------

The bivariate conditional logistic regression analysis results are shown in Table [3](#Tab3){ref-type="table"}, with matching accounting for the potential effect of age group and sex. The odds of people with ME/CFS reporting being unemployed or working part-time were 13.5-fold those of HCs (*p* \< 0.001) and 3.4-fold those of PWMS (*p* = 0.016). These findings are consistent with the working hours/week from people with ME in relation to HCs and PWMS \[odds ratio (OR) 17, *p* = 0.000; OR 4.6, *p* = 0.002, respectively\]. Additionally, we found odds of 8.5 for an annual income lower than £19,999 for people with ME/CFS when compared with HCs (*p* = 0.004), and 3.0 when compared with PWMS (*p* = 0.033). Furthermore, the odds of people with ME being on benefits was 3.8 of the HCs (*p* = 0.008) and 2.4 those of PWMS (0.048).Table 3Relationship between ME/CFS and socioeconomic variables (comparing people with ME/CFS with HCs or people with MS) using conditional logistic regressionIndependent variableDependent variablesOR*ZP* \> (*z*)95% CIPeople with ME/CFS (compared with HCs)Income \< £19,9998.52.860.0041.96--36.79Unemployed or working part-time13.53.55\< 0.0013.21--56.77On benefits3.82.660.0081.42--10.18Working up to 16 h/week17.03.890.0004.08--70.76People with ME/CFS (compared with people with MS)Income \< £19,9993.02.130.0331.09--8.25Unemployed or working part-time3.42.410.0161.25--9.21On benefits2.41.980.0481.01--5.85Working up to 16 h/week4.63.090.0021.75--12.01*ME* myalgic encephalomyelitis, *CFS* chronic fatigue syndrome, *HCs* healthy controls, *OR* odds ratio, *CI* confidence interval, *MS* multiple sclerosis

Discussion {#Sec15}
==========

Analysis of SF-36v2^TM^ data from this study suggests that in almost all areas measured, people with ME/CFS experience greater impact of their disease on life functioning than PWMS. Lower scores in the PCS, RP and SF domains for people with ME/CFS were consistent, corroborating the requirement for a 50% reduction in activity stipulated in the 2011 ICC \[[@CR13]\]. Markedly lower were the PF and SF scores, in line with findings from the National Outcomes Database in 2010 \[[@CR39]\] and supporting the earlier work of Nacul et al. \[[@CR24]\].

The study showed statistically significant differences in the number of work and study hours that people with ME/CFS were able to undertake compared with PWMS and HCs. There were also statistically significant differences in income received by people with ME/CFS, PWMS and HCs. People with ME/CFS were more likely to be unemployed or only able to work part-time than participants in the other two groups. There were noticeable decreases in income in both disease groups, however this was more pronounced in people with ME/CFS.

Study participants with ME/CFS or MS were asked about their income 6 months prior to disease onset and at the time of questionnaire completion; the time between these dates could be as short as 6 months, or as long as many years, depending on disease duration. Such reductions in income actually underestimate actual losses since inflation was not taken into account.

The above associations merit further exploration using longitudinal studies.

ME/CFS and the Role of Public Health {#Sec16}
------------------------------------

This study provides evidence of the disabling effects of ME/CFS, which negatively impact the HRQoL of people with the disease. Demonstrating that people with ME/CFS can be similarly, or, as suggested in this cohort, more disabled than PWMS, helps to validate ME/CFS as a debilitating illness. Such evidence could energise the public health community to coalesce with health services and various stakeholders to act on behalf of people with ME/CFS by informing policy and aiding advocacy. In turn, this could represent a further argument for increased funding for ME/CFS research and improvements in the planning of care and provision of rehabilitation services for people with ME/CFS. It could also advance the improved education of healthcare workers, many of whom are prejudiced towards ME/CFS and still do not recognise the disease \[[@CR40]\].

People with ME/CFS: Access to Employment {#Sec17}
----------------------------------------

These study findings suggest that people with ME/CFS are less able to continue employment after disease onset than PWMS, which may reflect the poorer physical functioning of people with ME/CFS and a lack of appropriate and effective treatments, and which could result from having a disease that is underrecognised and undersupported by employers \[[@CR41]\]. Some people with ME/CFS who are able to continue working do so by sacrificing all or much of the social life they would otherwise enjoy \[[@CR42]\]. Employers have been shown to be less accommodating to people without a visible disease or infirmity, such as occurs with back pain or depression \[[@CR43], [@CR44]\], and their behaviours towards people with ME/CFS are not always positive \[[@CR41]\], despite the requirements of the UK Equality Act 2010 \[[@CR45]\]. Public health authorities could play a major role in raising awareness of ME/CFS and educating employers around workplace support and modifications. Simple measures such as facilitating rest periods and adjusting light and sound exposure have been shown to be effective \[[@CR46]\].

The Impact of ME/CFS on Income {#Sec18}
------------------------------

These data demonstrate that in this sample, the income of people with ME/CFS decreased markedly following disease onset and was significantly lower than that of HCs. In this study, raw figures were used, unadjusted for inflation. If inflation were factored into these figures, the decrease in income would be even greater. In the conditional regression analysis, the dependent variables were likely to be interacting with each other; a multivariate model analysis would require a larger sample size to account for potential interaction. Repeating these analyses in a larger sample is recommended to further examine the associations between functional status of people with ME and income. These findings suggest that future analyses on HRQoL, using multivariate models for functional and socioeconomic variables, are worth pursuing.

Loss of employment for people with ME/CFS not only affects the self-worth and economic status of the individual, greatly impacting wellbeing and HRQoL, but also adds to the economic burden on government \[[@CR47]\]. Findings from this study are in line with 2012 data from specialist service centres \[[@CR39]\], which indicated that slightly more than half of 2000 people with ME/CFS had discontinued employment due to their symptoms. This also aligns with the more than 50% unemployment found in a systematic literature review of 37 studies in 2004 \[[@CR9]\]. Loss of productivity within the UK group was estimated then at over £22,000 per patient per annum \[[@CR39]\]. A recent report estimated the total cost to the UK economy at a minimum of £3.3 billion anually \[[@CR48]\]. Similar studies in the US have estimated that lost productivity for people with ME/CFS could be from \$9 billion to \$37 billion per annum \[[@CR49]\]. While investment may be essential to support employment opportunities, the decreased need for benefits and increased tax revenue from an employed population may help to address such costs \[[@CR50]\], and robust economic analysis should inform public health thinking.

Study Limitations {#Sec19}
-----------------

It is difficult to generalise these results. Data were collected from mainly White participants in South East England, therefore the results may not be applicable to minority populations, although there is no obvious indication that results would differ significantly in other population groups.

All HC SF-36v2^TM^ scores were \> 50, i.e. above a general population average, which might be due to selection bias because of the nature of recruitment \[[@CR51]\]. People with major illnesses were excluded and HCs agreeing to participate in a study of this kind are likely to be healthier than the average person.

All data were self-reported and some were retrospective, and therefore could have been subject to reporting and recall bias, particularly data on employment and income.

A multivariate analysis to account for potential confounding was not possible due to the likely degree of interaction between the outcome variables and potential confounding variables. Analysis with a larger sample size is planned for the future as the UK ME/CFS Biobank expands.

ME/CFS and MS can fluctuate in severity both day-to-day and over longer periods. Since symptoms can be quite disabling, participants with ME/CFS in particular were only able to participate during a time in which they were feeling able to do so, and many appointments had to be rescheduled. This presents a challenge for a cross-sectional analysis such as this since the answers provided may not be fully representative of the experience of participants with ME/CFS on a typical day insofar as the results may underrepresent the impact and/or severity of ME/CFS symptoms.

Conclusions {#Sec20}
===========

This study provides evidence for the reality of disability for many people with ME/CFS and the disease's effect on HRQoL and wellbeing. In this study population, the loss of functional status, as a proxy for disability, was greater in people with ME/CFS than PWMS. The disease conspicuously reduced SF in people with ME/CFS, and HRQoL may have been impacted by the subsequent social isolation \[[@CR52]\]. More people with ME/CFS than PWMS lost their jobs after becoming ill, and the income of people with ME/CFS decreased markedly more than for PWMS. Unemployment costs are borne by both the individual and society. The prevalence of ME/CFS, the evident reduction in HRQoL of those affected, and the economic cost of the illness to society should be powerful motivators for policy makers to encourage better funding of research to discover the cause of, and establish effective treatments for, this disease \[[@CR53]\].

Validating these findings will require further research with a larger sample size and in other population-based samples.

Electronic supplementary material
=================================

 {#Sec22}

Below is the link to the electronic supplementary material. Supplementary material 1 (DOCX 76 kb)
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